SG11201701837UA - N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway - Google Patents
N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathwayInfo
- Publication number
- SG11201701837UA SG11201701837UA SG11201701837UA SG11201701837UA SG11201701837UA SG 11201701837U A SG11201701837U A SG 11201701837UA SG 11201701837U A SG11201701837U A SG 11201701837UA SG 11201701837U A SG11201701837U A SG 11201701837UA SG 11201701837U A SG11201701837U A SG 11201701837UA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- signalling pathway
- wnt signalling
- acetamide derivatives
- pyridinyl
- Prior art date
Links
- MIQSEHQDHNIQNF-UHFFFAOYSA-N N-(2H-pyridin-1-yl)acetamide Chemical class CC(=O)NN1CC=CC=C1 MIQSEHQDHNIQNF-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000019491 signal transduction Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417829.7A GB201417829D0 (en) | 2014-10-08 | 2014-10-08 | Compounds |
| GBGB1511387.1A GB201511387D0 (en) | 2015-06-29 | 2015-06-29 | Compounds |
| PCT/GB2015/052939 WO2016055786A1 (en) | 2014-10-08 | 2015-10-08 | N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701837UA true SG11201701837UA (en) | 2017-04-27 |
Family
ID=54337304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701837UA SG11201701837UA (en) | 2014-10-08 | 2015-10-08 | N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10047079B2 (ru) |
| EP (1) | EP3204378B3 (ru) |
| JP (2) | JP6722178B2 (ru) |
| KR (1) | KR102525131B1 (ru) |
| CN (1) | CN107108565B (ru) |
| AU (1) | AU2015329784C1 (ru) |
| CA (1) | CA2960446C (ru) |
| CY (1) | CY1122243T1 (ru) |
| DK (1) | DK3204378T6 (ru) |
| EA (1) | EA034822B9 (ru) |
| ES (1) | ES2754349T7 (ru) |
| HR (1) | HRP20191826T4 (ru) |
| HU (1) | HUE046914T2 (ru) |
| IL (1) | IL251131B (ru) |
| LT (1) | LT3204378T (ru) |
| MX (1) | MX2017004637A (ru) |
| PH (1) | PH12017500611A1 (ru) |
| PL (1) | PL3204378T6 (ru) |
| PT (1) | PT3204378T (ru) |
| SG (1) | SG11201701837UA (ru) |
| SI (1) | SI3204378T1 (ru) |
| WO (1) | WO2016055786A1 (ru) |
| ZA (1) | ZA201701842B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795157B (zh) | 2014-10-08 | 2019-07-23 | 莱德克斯制药公共有限公司 | 作为Wnt信号传送途径的抑制剂的N-吡啶基乙酰胺衍生物 |
| HUE046914T2 (hu) | 2014-10-08 | 2020-04-28 | Redx Pharma Plc | N-piridinil-acetamid-származékok, mint a WNT jelátviteli út inhibitorai |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| US10793544B2 (en) | 2016-09-01 | 2020-10-06 | The Board Of Regents Of The University Of Texas System | Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| JP2019064975A (ja) * | 2017-10-03 | 2019-04-25 | 国立大学法人 熊本大学 | 抗がん剤 |
| JP7184383B2 (ja) * | 2018-02-01 | 2022-12-06 | ザ・ユニバーシティ・オブ・シドニー | 抗癌性化合物 |
| MA54133B1 (fr) | 2018-03-08 | 2022-01-31 | Incyte Corp | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
| JP2023508907A (ja) | 2019-12-20 | 2023-03-06 | テナヤ セラピューティクス， インコーポレイテッド | フルオロアルキル－オキサジアゾールおよびその使用 |
| WO2022094477A1 (en) * | 2020-11-02 | 2022-05-05 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancers having dysregulated wnt signaling pathways |
| GB202100526D0 (en) | 2021-01-15 | 2021-03-03 | Redx Pharma Plc | Pharmaceutical formulation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE236890T1 (de) | 1996-12-23 | 2003-04-15 | Bristol Myers Squibb Pharma Co | Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer |
| CA2275796A1 (en) | 1996-12-23 | 1998-07-02 | Donald Joseph Phillip Pinto | Nitrogen containing heteroaromatics as factor xa inhibitors |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| SE0203654D0 (sv) | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
| JP2006518738A (ja) * | 2003-02-12 | 2006-08-17 | トランス テック ファーマ，インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
| EP1802608A1 (en) | 2004-10-12 | 2007-07-04 | AstraZeneca AB | Quinazoline derivatives for use against cancer |
| WO2008137408A1 (en) * | 2007-04-30 | 2008-11-13 | Genentech, Inc. | Pyrazole inhibitors of wnt signaling |
| JP2011506445A (ja) | 2007-12-13 | 2011-03-03 | アムジエン・インコーポレーテツド | γ−セクレターゼ調節剤 |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| UY33469A (es) | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
| BR112014020233A2 (pt) * | 2012-02-28 | 2017-07-04 | Irm Llc | seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 |
| GB2513403A (en) | 2013-04-26 | 2014-10-29 | Agency Science Tech & Res | WNT pathway modulators |
| HUE046914T2 (hu) | 2014-10-08 | 2020-04-28 | Redx Pharma Plc | N-piridinil-acetamid-származékok, mint a WNT jelátviteli út inhibitorai |
| CN106795157B (zh) | 2014-10-08 | 2019-07-23 | 莱德克斯制药公共有限公司 | 作为Wnt信号传送途径的抑制剂的N-吡啶基乙酰胺衍生物 |
-
2015
- 2015-10-08 HU HUE15782041A patent/HUE046914T2/hu unknown
- 2015-10-08 LT LT15782041T patent/LT3204378T/lt unknown
- 2015-10-08 ES ES15782041T patent/ES2754349T7/es active Active
- 2015-10-08 US US15/514,046 patent/US10047079B2/en active Active
- 2015-10-08 DK DK15782041.6T patent/DK3204378T6/da active
- 2015-10-08 PT PT157820416T patent/PT3204378T/pt unknown
- 2015-10-08 KR KR1020177011823A patent/KR102525131B1/ko active IP Right Grant
- 2015-10-08 EP EP15782041.6A patent/EP3204378B3/en active Active
- 2015-10-08 PL PL15782041.6T patent/PL3204378T6/pl unknown
- 2015-10-08 CN CN201580054724.7A patent/CN107108565B/zh active Active
- 2015-10-08 MX MX2017004637A patent/MX2017004637A/es active IP Right Grant
- 2015-10-08 EA EA201790637A patent/EA034822B9/ru unknown
- 2015-10-08 HR HRP20191826TT patent/HRP20191826T4/hr unknown
- 2015-10-08 SG SG11201701837UA patent/SG11201701837UA/en unknown
- 2015-10-08 WO PCT/GB2015/052939 patent/WO2016055786A1/en active Application Filing
- 2015-10-08 CA CA2960446A patent/CA2960446C/en active Active
- 2015-10-08 SI SI201530941T patent/SI3204378T1/sl unknown
- 2015-10-08 JP JP2017518951A patent/JP6722178B2/ja active Active
- 2015-10-08 AU AU2015329784A patent/AU2015329784C1/en active Active
-
2017
- 2017-03-13 IL IL251131A patent/IL251131B/en active IP Right Grant
- 2017-03-15 ZA ZA2017/01842A patent/ZA201701842B/en unknown
- 2017-04-03 PH PH12017500611A patent/PH12017500611A1/en unknown
-
2018
- 2018-07-17 US US16/037,879 patent/US10793560B2/en active Active
-
2019
- 2019-10-10 CY CY20191101069T patent/CY1122243T1/el unknown
-
2020
- 2020-02-17 JP JP2020024726A patent/JP2020090542A/ja not_active Withdrawn
- 2020-09-01 US US17/009,322 patent/US11643408B2/en active Active
-
2023
- 2023-04-03 US US18/130,059 patent/US20230365549A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201702142UA (en) | N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors | |
| ZA201701842B (en) | N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway | |
| IL251584B (en) | Dihydropyrrolopyridines ror–gamma inhibitors | |
| IL246902B (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
| HK1225386A1 (zh) | 用作par-2信號傳導途徑抑制劑的咪唑並噠嗪類 | |
| ZA201704382B (en) | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg | |
| IL248550B (en) | History of indoline-2-one or pyrrolo-pyridin-2-one | |
| IL247366A0 (en) | Inhibitors of wnt signaling pathways | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
| GB201409783D0 (en) | Phthalimide derivatives as modulators of WNT pathway |